423 related articles for article (PubMed ID: 28511152)
1. [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].
Чопей ІВ; Івачевська ВВ; Чубірко КІ; Гряділь ТІ; Гечко ММ
Wiad Lek; 2017; 70(2):169-173. PubMed ID: 28511152
[TBL] [Abstract][Full Text] [Related]
2. [The diagnostics and clinical pattern of nonalcoholic fatty liver disease in patients with pre-diabetes and type 2 diabetes and obesity].
Чубірко КІ
Wiad Lek; 2017; 70(2):208-212. PubMed ID: 28511161
[TBL] [Abstract][Full Text] [Related]
3. EFFICACY OF COMPREHENSIVE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH PREDIABETES.
Ivachevska VV; Ivachevskyi MM; Hechko MM; Myhovych II; Blaga OS
Wiad Lek; 2023; 76(3):581-585. PubMed ID: 37057783
[TBL] [Abstract][Full Text] [Related]
4. [Impact of physical activity on anthropometric indices in patients with nonalcoholic fatty liver disease and pre-diabetes or type 2 diabetes].
Івачевська ВВ
Wiad Lek; 2017; 70(2):217-220. PubMed ID: 28511163
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes.
Cernea S; Cahn A; Raz I
Expert Rev Clin Pharmacol; 2017 May; 10(5):535-547. PubMed ID: 28276774
[TBL] [Abstract][Full Text] [Related]
6. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Ranjbar G; Mikhailidis DP; Sahebkar A
Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes.
Ann Intern Med; 2016 Sep; 165(5):. PubMed ID: 27322943
[No Abstract] [Full Text] [Related]
8. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice.
Onoyama T; Koda M; Okamoto T; Kishina M; Matono T; Sugihara T; Murawaki Y
Mol Med Rep; 2015 Nov; 12(5):6895-902. PubMed ID: 26397061
[TBL] [Abstract][Full Text] [Related]
10. Glycoregulation disorders and alterations of C reactive protein in nonalcoholic fatty liver disease.
Casoinic F; Sâmpelean D; Badău C
Rom J Intern Med; 2006; 44(4):419-26. PubMed ID: 18386618
[TBL] [Abstract][Full Text] [Related]
11. [ANTHROPOMETRIC CHARACTERISTICS AND PARAMETERS OF LIPID-CARBOHYDRATE METABOLISM IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND HYPERTENSION DEPENDING ON THE DEGREE OF HEPATIC STEATOSIS].
Babak О; Bashkirova А
Georgian Med News; 2018 Nov; (284):59-65. PubMed ID: 30618391
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease.
Scorletti E; Byrne CD
Annu Rev Nutr; 2013; 33():231-48. PubMed ID: 23862644
[TBL] [Abstract][Full Text] [Related]
13. [Steatosis and steatohepatitis in diabetic patient].
Hůlek P; Dresslerová I
Vnitr Lek; 2011 Apr; 57(4):364-7. PubMed ID: 21612059
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.
Abdelmoemen G; Khodeir SA; Zaki AN; Kassab M; Abou-Saif S; Abd-Elsalam S
Endocr Metab Immune Disord Drug Targets; 2019; 19(2):185-188. PubMed ID: 30009716
[TBL] [Abstract][Full Text] [Related]
15. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Brown GT; Kleiner DE
Metabolism; 2016 Aug; 65(8):1080-6. PubMed ID: 26775559
[TBL] [Abstract][Full Text] [Related]
16. Subclinical hypothyroidism in patients with non-alcoholic fatty liver disease at the background of carbohydrate metabolism disorders.
Feisa SV; Chopei IV
Wiad Lek; 2018; 71(2 pt 1):261-264. PubMed ID: 29729151
[TBL] [Abstract][Full Text] [Related]
17. [A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis].
Nakamoto K; Obata T; Hirasawa A; Kim KI; Kim SR; Tokuyama S
Yakugaku Zasshi; 2016; 136(4):583-9. PubMed ID: 27040343
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD.
Nobili V; Alisi A; Musso G; Scorletti E; Calder PC; Byrne CD
Crit Rev Clin Lab Sci; 2016; 53(2):106-20. PubMed ID: 26463349
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.
Jump DB; Lytle KA; Depner CM; Tripathy S
Pharmacol Ther; 2018 Jan; 181():108-125. PubMed ID: 28723414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
